GMAB
Price:
$25.08
Market Cap:
$15.45B
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSC...[Read more]
Industry
Biotechnology
IPO Date
2009-06-01
Stock Exchange
NASDAQ
Ticker
GMAB
According to Genmab A/S’s latest financial reports and current stock price. The company's current Enterprise Value is 19.28B. This represents a change of -82.26% compared to the average of 108.72B of the last 4 quarters.
The mean historical Enterprise Value of Genmab A/S over the last ten years is 112.92B. The current 19.28B Enterprise Value has changed 1.61% with respect to the historical average. Over the past ten years (40 quarters), GMAB's Enterprise Value was at its highest in in the December 2022 quarter at 182.96B. The Enterprise Value was at its lowest in in the June 2018 quarter at 59.14B.
Average
112.92B
Median
108.28B
Minimum
62.24B
Maximum
183.01B
Discovering the peaks and valleys of Genmab A/S Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 70.83%
Maximum Annual Enterprise Value = 183.01B
Minimum Annual Increase = -30.80%
Minimum Annual Enterprise Value = 62.24B
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 129.82B | 48.13% |
| 2024 | 87.64B | -30.80% |
| 2023 | 126.65B | -30.80% |
| 2022 | 183.01B | 11.96% |
| 2021 | 163.46B | 6.42% |
| 2020 | 153.59B | 70.83% |
| 2019 | 89.91B | 44.46% |
| 2018 | 62.24B | -1.24% |
| 2017 | 63.01B | -9.89% |
| 2016 | 69.93B | 32.39% |
The current Enterprise Value of Genmab A/S (GMAB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
114.70B
5-year avg
138.11B
10-year avg
112.92B
Genmab A/S’s Enterprise Value is greater than Incyte Corporation (18.26B), less than United Therapeutics Corporation (22.10B), less than Royalty Pharma plc (31.97B), less than Tenet Healthcare Corporation (25.29B), less than Illumina, Inc. (25.73B), less than Quest Diagnostics Incorporated (29.06B), less than Roivant Sciences Ltd. (20.29B), greater than Summit Therapeutics Inc. (10.80B), less than Zimmer Biomet Holdings, Inc. (24.18B), greater than Exelixis, Inc. (13.30B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 18.26B | $21.68B | |
| 22.10B | $23.17B | |
| 31.97B | $23.60B | |
| 25.29B | $15.04B | |
| 25.73B | $24.35B | |
| 29.06B | $22.48B | |
| 20.29B | $21.61B | |
| 10.80B | $10.86B | |
| 24.18B | $17.13B | |
| 13.30B | $13.35B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genmab A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Genmab A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Genmab A/S's Enterprise Value?
What is the highest Enterprise Value for Genmab A/S (GMAB)?
What is the 3-year average Enterprise Value for Genmab A/S (GMAB)?
What is the 5-year average Enterprise Value for Genmab A/S (GMAB)?
How does the current Enterprise Value for Genmab A/S (GMAB) compare to its historical average?